Drug Profile
PRO 542
Alternative Names: CD4 IgG2Latest Information Update: 19 Jun 2020
Price :
$50
*
At a glance
- Originator Columbia University
- Class Antivirals; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins
- Mechanism of Action HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 04 Nov 2003 Data presented at the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA-2003) have been added to adverse events and Viral Infections antimicrobial activity sections
- 11 Dec 2002 A clinical study has been added to the Viral Infections antimicrobial activity section